1. In Vivo
  2. >>Market Access

Mifepristone Access Swings In The Balance In Post-Roe World

30 Million US Women Of Reproductive Age Have Now Lost Abortion Access

 
• By Chloe Kent

The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.

Protestor holding a sign reading 'Abortion is healthcare'
Around 40% of reproductive-age women in the US have now lost access to abortion care • Source: Shutterstock

Since the US Supreme Court’s ruling on Dobbs v. Jackson Women's Health Organization on 24 June, which overturned the 1973 Roe v. Wade judgement that conferred the constitutional right to an abortion, over a dozen states have moved to enact restrictions on the procedure.

How Is A Medical Abortion Performed?

In a medical abortion, two different medications are taken: mifepristone, which blocks the action of progesterone on the uterus and prevents further growth of the pregnancy, followed 24 to 48 hours later by misoprostol, which causes the uterus to contract and expel the pregnancy. In the US, this process is approved for use up to 10 weeks gestation. In 2020, medication abortion accounted for 54% of abortions in the US according to the Guttmacher Institute

Eleven states are currently enforcing near-total abortion bans, while six others have implemented restrictions on access to the procedure since the Dobbs judgement and eight more are currently embroiled in legal challenges to their bans. Of the 75 million American women of reproductive age, nearly 30 million now have limited or no access to abortion

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

More from In Vivo

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.